Drug Trial Radar · NCT05460533
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
Jul 12, 2022
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- First posted
- Jul 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 day, up to 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.
Conditions
- B-cell Acute Lymphoblastic Leukemia
Interventions
TisagenlecleucelBiological
Tisagenlecleucel will be infused based on institutional guidelines. Reinfusion of tisagenlecleucel will occur 30-60 days following the first dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- decrease the loss of peripheral BCA rateTime frame: 6 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California
Stanford University (Data Collection Only)
Stanford, California
Children's Hospital Colorado (Data Collection Only)
Aurora, Colorado
Johns Hopkins University (Data Collection Only)
Baltimore, Maryland
Memorial Sloan Kettering Cancer Center
New York, New York
Cincinnati Children's Hospital Medical Center (Data Collection Only)
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.